[go: up one dir, main page]

CR8904A - Formulaciones estabilizadoras - Google Patents

Formulaciones estabilizadoras

Info

Publication number
CR8904A
CR8904A CR8904A CR8904A CR8904A CR 8904 A CR8904 A CR 8904A CR 8904 A CR8904 A CR 8904A CR 8904 A CR8904 A CR 8904A CR 8904 A CR8904 A CR 8904A
Authority
CR
Costa Rica
Prior art keywords
protein
storing
methods
relatively low
formulation
Prior art date
Application number
CR8904A
Other languages
English (en)
Inventor
Li Li
Angela Kantor
Shannon B Macmillan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8904A publication Critical patent/CR8904A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen formulaciones que son adecuadas para el almacenamiento de proteinas, tal como anticuerpos, sobre un rango relativamente amplio de concentraciones de proteina, pH, y tipos de tampon. Tambien se describen metodos de almacenamiento de una proteina y metodos para identificar una formulacion adecuada para el almacenamiento de una proteina especifica. En general, una formulacion que contiene poco o nada de surfactante, desde nada a concentraciones relativamente bajas de sal, y que requiere una concentracion de tampon relativamente baja.
CR8904A 2004-08-13 2007-02-06 Formulaciones estabilizadoras CR8904A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60131104P 2004-08-13 2004-08-13

Publications (1)

Publication Number Publication Date
CR8904A true CR8904A (es) 2007-08-28

Family

ID=35908214

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8904A CR8904A (es) 2004-08-13 2007-02-06 Formulaciones estabilizadoras

Country Status (18)

Country Link
US (1) US8871201B2 (es)
EP (1) EP1784219B1 (es)
JP (1) JP4948407B2 (es)
KR (1) KR20070092197A (es)
CN (1) CN101022831A (es)
AR (1) AR051009A1 (es)
AU (1) AU2005272603A1 (es)
BR (1) BRPI0514340A (es)
CA (1) CA2575870A1 (es)
CR (1) CR8904A (es)
EC (1) ECSP077246A (es)
ES (1) ES2637854T3 (es)
IL (1) IL181265A0 (es)
MX (1) MX2007001599A (es)
NO (1) NO20070930L (es)
RU (1) RU2007109062A (es)
TW (1) TW200621282A (es)
WO (1) WO2006020935A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
JP2009534390A (ja) * 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
US20080070230A1 (en) * 2006-06-12 2008-03-20 Wyeth Methods for reducing or preventing liquid-liquid phase separation in high concentration protein solutions
EP1950225A1 (de) * 2007-01-25 2008-07-30 Octapharma AG Verfahren zur Steigerung von Proteinausbeuten
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
CA2707483A1 (en) * 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20110096553A (ko) * 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
NZ613809A (en) * 2009-05-04 2015-02-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2011026945A1 (en) 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
AU2012279205B2 (en) 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
CA2857502C (en) 2011-11-30 2019-08-13 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2014099636A1 (en) * 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Liquid formulations for an anti-tnf alpha antibody
WO2015065954A1 (en) 2013-11-04 2015-05-07 Pfizer, Inc. Anti-efna4 antibody-drug conjugates
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
JP6629831B2 (ja) * 2014-07-21 2020-01-15 アンチェインド ラブス Δｇ値の濃度依存性に基づくタンパク質凝集の定量
IL255189B2 (en) 2015-04-29 2024-04-01 Radius Pharmaceuticals Inc A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
US11428695B2 (en) 2016-08-18 2022-08-30 Regeneron Pharmaceuticals, Inc. Concentration-dependent self-interaction assay
KR102446838B1 (ko) 2016-10-21 2022-09-26 암젠 인크 약학적 제형 및 그의 제조 방법
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
PH12021551950A1 (en) 2019-02-12 2022-05-23 Radius Pharmaceuticals Inc Processes and compounds
US20230167153A1 (en) * 2020-05-01 2023-06-01 Kashiv Biosciences, Llc An improved process of purification of protein
TW202245823A (zh) * 2021-01-14 2022-12-01 南韓商韓兀生物製藥股份有限公司 無穩定劑或實質上無穩定劑之含有天凡諾賽普特（ｔａｎｆａｎｅｒｃｅｐｔ）的穩定眼用組成物
CN115541895B (zh) * 2022-11-29 2023-05-19 天津德祥生物技术股份有限公司 一种提高微流控反定检测卡灵敏度的配方液及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0041768B1 (en) * 1980-04-24 1987-11-11 Beecham Group Plc Beta-lactam compounds, their preparation and use
GB8518416D0 (en) 1985-07-22 1985-08-29 Beecham Group Plc Compounds
US5869053A (en) * 1988-03-04 1999-02-09 Cancer Research Campaign Technology, Ltd. 5T4 antigen from human trophoblasts
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
PT1012259E (pt) * 1997-06-04 2009-11-06 Oxford Biomedica Ltd Vector dirigido a tumor
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
WO2002030463A2 (en) * 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20050031627A1 (en) * 2002-01-03 2005-02-10 Mazzola Gregory J Methods for preparing immunoconjugates
HUE030806T2 (hu) * 2002-05-02 2017-05-29 Wyeth Holdings Llc Calicheamicin származék-hordozó konjugátumok
CN1671741A (zh) 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2004266216A1 (en) 2003-08-14 2005-03-03 Ludwig Institute For Cancer Research Anti-Lewis Y anti-idiotypic antibodies and uses thereof
GT200500255A (es) * 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina

Also Published As

Publication number Publication date
TW200621282A (en) 2006-07-01
NO20070930L (no) 2007-05-14
ES2637854T3 (es) 2017-10-17
JP4948407B2 (ja) 2012-06-06
US20060115472A1 (en) 2006-06-01
AU2005272603A1 (en) 2006-02-23
CA2575870A1 (en) 2006-02-23
CN101022831A (zh) 2007-08-22
EP1784219A2 (en) 2007-05-16
EP1784219B1 (en) 2017-05-17
IL181265A0 (en) 2007-07-04
MX2007001599A (es) 2007-04-10
BRPI0514340A (pt) 2008-06-10
ECSP077246A (es) 2007-05-30
WO2006020935A2 (en) 2006-02-23
JP2008515775A (ja) 2008-05-15
AR051009A1 (es) 2006-12-13
US8871201B2 (en) 2014-10-28
RU2007109062A (ru) 2008-09-20
WO2006020935A3 (en) 2007-03-08
KR20070092197A (ko) 2007-09-12
EP1784219A4 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
CR8904A (es) Formulaciones estabilizadoras
CR10290A (es) Metodos para reducir la aglomeracion de proteina
CY1121461T1 (el) Συνθεσεις που περιλαμβανουν δυσδιαλυτους στο νερο φαρμακευτικους παραγοντες και αντιμικροβιακους παραγοντες
TR201905081T4 (tr) Protein içeren formülasyonların stabilizasyonu için yararlı bileşimler ve yöntemler.
CR9620A (es) Composicion agricola
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
PE20121170A1 (es) Composicion de insulina de accion prolongada
ECSP088962A (es) Nuevos herbicidas
PE20120342A1 (es) Formulacion de anticuerpo
AR084285A1 (es) Composiciones inmunogenicas
CO6640258A2 (es) Formulaciones de anticuerpos de alta concentración
MX2010008416A (es) Composiciones antimicrobianas y metodos de uso de las mismas.
CO6382079A2 (es) Composiciones insecticidas estables a base de sulfoximina
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
PE20070723A1 (es) Imidazopirazinas como inhibidores de quinasas dependientes de ciclina
PE20091783A1 (es) Anticuerpos anti-factor d humanizados
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
BR112015022210A8 (pt) formulações de anticorpo
ES2570599T3 (es) Composición suave para desinfección cutánea
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
AR086473A1 (es) Variantes de fitasa sintetica
PE20070437A1 (es) FORMULACION ACUOSA hFSH
CL2011001306A1 (es) Composicion antimicrobiana que comprende una sal de plata soluble, una alcanolamida, y/o aminoalcohol, un ph 6 o superior; composicion limpiadora que comprende un surfactante, una sal de plata soluble, una alcanolamida, y/o aminoalcohol.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)